GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Wednesday

GT Biopharma (NASDAQ:GTBP) is projected to issue its results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

GT Biopharma Stock Performance

Shares of GT Biopharma stock opened at $0.48 on Wednesday. The firm has a market cap of $14.99 million, a PE ratio of -0.07 and a beta of 1.28. The business’s 50 day simple moving average is $0.53 and its 200 day simple moving average is $0.66. GT Biopharma has a 52-week low of $0.39 and a 52-week high of $3.85.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of GT Biopharma in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).